Sosei Says `Rapidly' Renewing Pipeline After Allergan DealBy
CEO-Elect Peter Bains says "a lot more to come" for company
Tokyo-based biopharmaceutical firm could make bolt-on deals
Sosei Group is "rapidly" replenishing its portfolio after announcing a $125 million drug development agreement with Allergan Plc last week, the Japanese pharmaceutical company’s incoming chief executive officer said.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.